Moleculin Biotech Files 8-K
Ticker: MBRX · Form: 8-K · Filed: Oct 23, 2025 · CIK: 1659617
Sentiment: neutral
Topics: sec-filing, disclosure
TL;DR
Moleculin Biotech filed an 8-K on Oct 23, 2025. Standard disclosure.
AI Summary
Moleculin Biotech, Inc. filed an 8-K on October 23, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD Disclosure and includes Financial Statements and Exhibits. No specific financial figures or material events beyond the filing itself are detailed in the provided text.
Why It Matters
This filing indicates Moleculin Biotech is making disclosures to the SEC, which could relate to ongoing business operations or regulatory compliance.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain information about specific risks or material events.
Key Players & Entities
- Moleculin Biotech, Inc. (company) — Registrant
- October 23, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 47-4671997 (identifier) — I.R.S. Employer Identification No.
- 5300 Memorial Drive, Suite 950, Houston, TX 77007 (address) — Principal executive offices
- 713-300-5160 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and to include Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on October 23, 2025.
What is the company's full legal name and state of incorporation?
The company's full legal name is Moleculin Biotech, Inc., and it is incorporated in Delaware.
What is the principal executive office address for Moleculin Biotech, Inc.?
The principal executive office address is 5300 Memorial Drive, Suite 950, Houston, TX 77007.
What is the I.R.S. Employer Identification Number for Moleculin Biotech, Inc.?
The I.R.S. Employer Identification Number for Moleculin Biotech, Inc. is 47-4671997.
Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-10-23 08:00:18
Filing Documents
- mbrx20251020_8k.htm (8-K) — 30KB
- ex_874352.htm (EX-99.1) — 18KB
- a01.jpg (GRAPHIC) — 10KB
- 0001437749-25-031574.txt ( ) — 208KB
- mbrx-20251023.xsd (EX-101.SCH) — 3KB
- mbrx-20251023_def.xml (EX-101.DEF) — 11KB
- mbrx-20251023_lab.xml (EX-101.LAB) — 15KB
- mbrx-20251023_pre.xml (EX-101.PRE) — 11KB
- mbrx20251020_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure On October 23, 2025, Moleculin Biotech, Inc. (the "Company"), issued a press release which announced that the Company has entered into an agreement with Atlantic Health System, Inc. to commence an investigator-initiated Phase 1B/2 single-arm study evaluating Annamycin for third-line ("3L") treatment of advanced pancreatic cancer. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated October 23, 2025 104 Cover page Interactive Data File (formatted as Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOLECULIN BIOTECH, INC. Date: October 23, 2025 By: /s/ Jonathan P. Foster Jonathan P. Foster